Literature DB >> 12498928

Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.

Kenneth Ihenetu1, Areles Molleman, Mike E Parsons, Clifford J Whelan.   

Abstract

We have investigated the effects of cannabinoid agonists and antagonists on tumour necrosis factor-alpha (TNF-alpha)-induced secretion of interleukin-8 from the colonic epithelial cell line, HT-29. The cannabinoid receptor agonists [(-)-3-[2-hydroxy-4-(1,1-dimethyl-heptyl)-phenyl]4-[3-hydroxypropyl]cyclo-hexan-1-ol] (CP55,940); Delta-9-tetrahydrocannabinol; [R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl) methyl] pyrrolo[1,2,3-de]1,4-benzoxazin-6-yl](1-naphthyl) methanone mesylate] (WIN55,212-2) and 1-propyl-2-methyl-3-naphthoyl-indole (JWH 015) inhibited TNF-alpha induced release of interleukin-8 in a concentration-dependent manner. The less active enantiomer of WIN55212-2, [S(-)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]1,4-benzoxazin-6-yl](1-naphthyl) methanone mesylate (WIN55212-3), and the cannabinoid CB(1) receptor agonist arachidonoyl-2-chloroethylamide (ACEA) had no significant effect on TNF-alpha-induced release of interleukin-8. The cannabinoid CB(1) receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1,4-pyrazole-3-carboxamide hydrochloride (SR141716A; 10(-6) M) antagonised the inhibitory effect of CP55,940 (pA(2)=8.3+/-0.2, n=6) but did not antagonise the inhibitory effects of WIN55212-2 and JWH 015. The cannabinoid CB(2) receptor antagonist N-(1,S)-endo1,3,3-trimethylbicyclo(2,2,1)heptan-2-yl)-5(4-chloro-3-methyl-phenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528; 10(-6) M) antagonised the inhibitory effects of CP55,940 (pA(2)=8.2+/-0.8, n=6), WIN55212-2 (pA(2)=7.1+/-0.3, n=6) and JWH 015 (pA(2)=7.6+/-0.3, n=6), respectively. Western immunoblotting of HT-29 cell lysates revealed a protein with a size that is consistent with the presence of cannabinoid CB(2) receptors. We conclude that in HT-29 cells, TNF-alpha-induced interleukin-8 release is inhibited by cannabinoids through activation of cannabinoid CB(2) receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12498928     DOI: 10.1016/s0014-2999(02)02698-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  21 in total

1.  Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice.

Authors:  M Salaga; H Zatorski; M Zielińska; P Mosinska; J-P Timmermans; R Kordek; M Storr; J Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-14       Impact factor: 3.000

2.  The major pathway by which polymeric formula reduces inflammation in intestinal epithelial cells: a microarray-based analysis.

Authors:  Lily Nahidi; Susan M Corley; Marc R Wilkins; Jerry Wei; Moftah Alhagamhmad; Andrew S Day; Daniel A Lemberg; Steven T Leach
Journal:  Genes Nutr       Date:  2015-07-17       Impact factor: 5.523

3.  Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability.

Authors:  A Alhamoruni; K L Wright; M Larvin; S E O'Sullivan
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Endocannabinoid overactivity and intestinal inflammation.

Authors:  V Di Marzo; A A Izzo
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

5.  Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.

Authors:  Jamal El Bakali; Giulio G Muccioli; Mathilde Body-Malapel; Madjid Djouina; Frédérique Klupsch; Alina Ghinet; Amélie Barczyk; Nicolas Renault; Philippe Chavatte; Pierre Desreumaux; Didier M Lambert; Régis Millet
Journal:  ACS Med Chem Lett       Date:  2014-12-04       Impact factor: 4.345

6.  Cannabinoids pharmacological effects are beyond the palliative effects: CB2 cannabinoid receptor agonist induced cytotoxicity and apoptosis in human colorectal cancer cells (HT-29).

Authors:  Aylar Alenabi; Hassan Malekinejad
Journal:  Mol Cell Biochem       Date:  2021-04-22       Impact factor: 3.396

Review 7.  Cannabinoids and intestinal motility: welcome to CB2 receptors.

Authors:  Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2004-07-26       Impact factor: 8.739

8.  Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.

Authors:  E Gkoumassi; B G J Dekkers; M J Dröge; C R S Elzinga; M Schmidt; H Meurs; J Zaagsma; S A Nelemans
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

Review 9.  Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation.

Authors:  K L Wright; M Duncan; K A Sharkey
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

Review 10.  Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Authors:  Hester van Diepen; Eberhard Schlicker; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-25       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.